{"name":"Blueprint Medicines Corporation","slug":"blueprint-medicines-corporation","ticker":"","exchange":"","domain":"blueprintmedicinescorporation.com","description":"Blueprint Medicines Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing targeted therapies for patients with genomically defined diseases. The company's pipeline includes several compounds in various stages of clinical development, primarily in oncology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BLU-808","genericName":"BLU-808","slug":"blu-808","indication":"Gastrointestinal stromal tumor (GIST)","status":"phase_2"}]}],"pipeline":[{"name":"BLU-808","genericName":"BLU-808","slug":"blu-808","phase":"phase_2","mechanism":"BLU-808 is a potent and selective KIT inhibitor.","indications":["Gastrointestinal stromal tumor (GIST)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPMDlzRmdLZl9sYmZCRTdUdUU1MTVGUkxCeExWYW1HdHBBcTNPNGx2cjJXb0pBSUlMLUdHa2dINUZ3YzU1VFJiMGFSSTBkLWxaNGRjM19BLTIzbkF5VnJ6akM1d0x2MWxhQzVVYjQzVk5ic0RSSk5yN29naHZGc2pFcHNxT18yUTR1enMw?oc=5","date":"2025-11-17","type":"pipeline","source":"Contract Pharma","summary":"AdvanCell Appoints Philina Lee as CEO - Contract Pharma","headline":"AdvanCell Appoints Philina Lee as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOa3JsNENYOTNfU1pzSzMxdEFNNTBhNzhPd3RYN3EtLWxDOFFiZFBOMWlNMVpCaFV2UVRIWkR3UThWMjNlX1dsMUFWQmZfTFJpdUNRR1ZheXBjODl2RUU2OFhneFMzbl9rVVgzaEJzaDlDdTNwMkZhMXdkRlQwMmh1SzV5eERYckNCLWFqRjkxbmpTX05jcGNMenBpNFYxNm1LNjJWcFgxS21aVjBZdUUyNg?oc=5","date":"2025-11-12","type":"pipeline","source":"BioSpace","summary":"Five Trends That Got Everyone Talking in Pharma and Biotech This Year - BioSpace","headline":"Five Trends That Got Everyone Talking in Pharma and Biotech This Year","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPalU2aW00Y1JJRVhTQVE2ZnlzNTV1Vzk1U2tJaVVDUFdncVBjOTdqWE1LY1JJQ19IQjd1amtybnRZSHhwanRBcG1XeUtadm1NSnB6U29EMjlDTXBqenBRRVJLMG9mY2Y0b0gxSU5fLTdfVnVEN1dRTTRUZ3FZUm9yZ095bzNNU1pwWkpzeUo1Yw?oc=5","date":"2025-07-21","type":"pipeline","source":"Pharmaceutical Technology","summary":"Sanofi concludes Blueprint Medicines acquisition - Pharmaceutical Technology","headline":"Sanofi concludes Blueprint Medicines acquisition","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-12","type":"trial","source":"PR Newswire","summary":"Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses - P","headline":"Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Ter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOV3hXbi11LUp1ajA5QmZVZk9TVU53dTVrUFJTMU5FaEptQUFWQXFUZDZuTnI2a0oxai1HMkM1Y0lKX1oxWV80TzVfUUV2ZlB4UVRjcXU4ejVvVGRWNGtKczZMRnRKMjJnOWN0TWlDUjZCOGdHTmYxVDF2T2lhZkMxU2o4QVotYzZhVndpcFdxbldzWGxzRXg1Y0pJeVlob2FyR3Rza0h4NmxUVk5UdVE?oc=5","date":"2025-06-03","type":"deal","source":"The Business Journals","summary":"Sanofi to buy Blueprint Medicines for $9.1B - The Business Journals","headline":"Sanofi to buy Blueprint Medicines for $9.1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOU2dLRkwtT0trUXpwc1RobXdVNlJmR2JjaDNhTGlBaF8wMXo0VlI4R3ZJeW0ycDZpcjhzZ2tETDc0VkFvTWRxNU1PbnQyNWxTc3I3dEd4NEJnWkxJQ08xU3kzSlhSZC1aRUZudGpRVVQwNlNMYzU1TDlLTTFfdGFlYnBVeEROSnpBMTZVVjdzQmNNZkVnMWlzV0RPSQ?oc=5","date":"2025-06-03","type":"deal","source":"Pharma Voice","summary":"Sanofi to acquire Blueprint for up to $9.5B - Pharma Voice","headline":"Sanofi to acquire Blueprint for up to $9.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNa2hHZmEwSjNrSng0Nl9lTXh1bkNlQ3M0YzBUSUN0Y2NscHVuZExZbzk4Nmo2bUZ3WFJHa0R4N1NqVm5NTzNpODZaM0hvc1RpaTV3djF3QjYyNlFqT0w1TDBaLVRuT3k4QmVvMld5bWlVa3MxRmNRQXpRVTRWb2FYa2xGZFpaR3hhV09IRXdxQUkwM1BMVkFLbDNLR1FVR2o4Qm15ZGk3U2E5SVQ0VmF6VVY1RndmSjJnNnkxak9RWTR3Zw?oc=5","date":"2025-06-02","type":"deal","source":"Reuters","summary":"Sanofi to buy US biopharma group Blueprint for up to $9.5 billion - Reuters","headline":"Sanofi to buy US biopharma group Blueprint for up to $9.5 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNaXFIVHdtZGgwcUo1ZnJxbFVjQ1JGUnpwYmpndjhLTS10ZW5nN3RzZ0U0UUhhaE9RMUcteUJReS10QkM2SFF2bXBidzFpQnhNLXZ4ejVDQ09sSGdFVEdNTHROQ016aU1tNDFMQ1A3WGd4Y1p1ckkyUWw0NW9UQ3JxOFBtTzMtNG12XzVJWlNHemhiR1Qzd1dyMzRMVmR2RWtVNFo3VkdPMWkxeThkZmY3Yl82OVI?oc=5","date":"2025-06-02","type":"pipeline","source":"Investopedia","summary":"Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover - Investopedia","headline":"Blueprint Medicines Stock Soars as Biotech Agrees to Over $9B Sanofi Takeover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQRl9uQkN2N1dOeXByZVhDQUxDdFBBSnFzcG4tQS1uWk04YV9yV0hHMk1xX0c4WGN5ZVF1bE54TkJHendsZUVGeUFlOHg0MTJjeTFCNGUtYjl2WDlXLWp6cHJackt5NmNRZ3VUWkltWVNCQlA2X1NObHUyUnlMZHpqSUVTV044S3FTM1M4OA?oc=5","date":"2025-06-02","type":"deal","source":"statnews.com","summary":"Sanofi to buy Blueprint Medicines in deal worth more than $9 billion - statnews.com","headline":"Sanofi to buy Blueprint Medicines in deal worth more than $9 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPbXFKZ0xmUVgzS0ZQQTROSmVXN05uNVd2aXFFSVY5Qi1aYjV3a1BfZGVsNjhGSnU5SVVwQ3R3NDg1RTZKSnlmQ1E0ajhqc0FUc1E3aEtTdGVEQVR1X2tQWEgtSFVTblNNQ1ZpbVhHM1ZrM2pLSFpxTkFneXRfRFNaWmhlZGtjRWtWLVZ5b0pHc2lDeE9vRTZFTEo4ektSYWM?oc=5","date":"2025-06-02","type":"pipeline","source":"Fierce Pharma","summary":"With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B - Fierce Pharma","headline":"With Opella proceeds burning a hole in its pocket, Sanofi snaps up Blueprint for $9.1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5vVTZKNEk4SW5NejdUSmNrTDFlc0lvamtGeG1vT0pic2RVZG1na2V4THM3VjhVZW4xbW1ub3pweGNYcHFZMkc5dGE1elgzRndSWVhuNFhFSXBVV0xVTnpXd0I5Z0c2emltNTdNUnR4T2Z4dGMxYUs3TFRSZ0tDdw?oc=5","date":"2025-06-02","type":"deal","source":"Yahoo Finance","summary":"French pharma firm Sanofi in $9.5bn plan to buy Blueprint Medicines - Yahoo Finance","headline":"French pharma firm Sanofi in $9.5bn plan to buy Blueprint Medicines","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxPU0lfb3JuanBtUjRDM1dtTmxrdG1idXpCNFVXaUcwUVdEdlNGTDhjYzU0ZGx0ekxval9YWkJ0VWFyOEJLUUtGdU9aSDFPa1BOVVE5c3QxVWhpREdxVTBjQ3JLS08wdUJid3praE55NDNXeGpfWUd3YlA5T0tpVi1CM3RkUDJzNXU0cE9CZHlXdzJmTU4yY3pQWGxnUVhXOVhocU9WUWE2T2FPRHhzLW1kLUQ0UmpVX0tuSmJuNzJucE1OMGJla1V5QVdFbjF3VVhyQnJkNHU4RklIQUh1ZGJGbzNjWWN5aldTY0tiZFNEREtFVnZWRm5BaTFMZXNLcEg2MVZDWg?oc=5","date":"2022-06-30","type":"deal","source":"Sixth Street","summary":"Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Royalty Pharma - Sixth Street","headline":"Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and Roya","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}